G. Bell

The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design.

M. Cousins, Karen Pickthorn, Saling Huang, 2013, Pain medicine.

Pharmacokinetics and immunogenicity profiles for fully human monoclonal antibodies against soluble and membrane bound antigens in patients with psoriasis and melanoma

M. Tabrizi, L. Roskos, G. Bell, 2004 .

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor

R. Kewalramani, G. Block, D. Bushinsky, 2015, American Journal of Nephrology.

A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients

G. Block, K. Martin, Saling Huang, 2015, Current medical research and opinion.

AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.

D. Power, G. Block, K. Martin, 2014, Kidney international.

Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects

M. Peacock, K. Martin, Karen Pickthorn, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.

P. Armstrong, C. Granger, K. Mahaffey, 2014, American heart journal.

A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain.

Saling Huang, G. Bell, J. Moodie, 2013, Pain medicine.

A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects

Ping Chen, Saling Huang, G. Bell, 2014, Journal of clinical pharmacology.

Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

J. Tomlinson, D. Maclean, D. Mendel, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.

D. Atar, H. White, H. Suryapranata, 2014, European heart journal.

Utility of CMR Markers of Myocardial Injury in Predicting LV Functional Recovery: Results from PROTECTION AMI CMR Sub-study.

G. Figtree, D. Leong, R. Woodman, 2015, Heart, lung & circulation.

Pre-Clinical Characterization of a Novel Fusion Protein (AT-03), with Pan-Amyloid Binding and Removal

S. Kennel, J. S. Foster, J. Wall, 2021, Blood.